Postpardum Depression Drug Breakthrough, BlackRock’s Risky Software Bet, Tiffany Earnings

Bloomberg Businessweek Editor Joel and Bloomberg News Health Care Reporter Cynthia Koons discuss the trials and tribulations of postpartum depression drug Zulresso. Annie Massa, Bloomberg News Investing Reporter, talks about BlackRock buying risky software provider eFront. Charlie Bobrinskoy, Head of Investment Group at Ariel Investments, explains why Tiffany is a good company but not awlays a good stock. Megan Bent, Founder of Harbinger Ventures, discusses the state of funding for women entrepreneurs. Matthew Wadiak, Co-Founder of Blue Apron, talks about launching Cooks Venture a next generation food company saving the planet one chicken at a time. And we Drive to the Close with Charles Lemonides, Chief Investment Officer at ValueWorks. Hosts: Carol Massar and Jason Kelly. Producer: Paul Brennan See omnystudio.com/listener for privacy information.